AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Innoplexus Announces New North American Affiliate Helmed by Former Merck KGaA Executive
Leader in Pharmaceutical Research AI expands North American Presence.
HOBOKEN, NJ, May 10, 2018 /24-7PressRelease/ — Innoplexus, a leader in artificial intelligence and data analytics solutions for pharmaceutical and life science research, announced today the opening of Innoplexus Americas. This new affiliate will focus on empowering pharmaceutical companies in the United States and Latin America to achieve new heights of creativity and innovation through augmented data analytics capabilities.
Innoplexus has hired experienced pharmaceutical executive Lawrence Ganti to serve as Innoplexus America’s inaugural CEO. Mr. Ganti comes to Innoplexus with a plethora of leadership experience in the pharmaceutical space. Most recently, he was President of Merck KGaA’s Latin American business. His prior experience includes General Manager roles with Merck in Brasil and India. He was also Head of Commercial Development for Merck’s Emerging Markets Business Unit, where he consolidated the strategy and business analytics functions. Prior to his roles with Merck, Mr. Ganti held positions with McKinsey & Company and various technology starts-ups.
Mr. Ganti’s experience as a global pharmaceutical leader gives him an insider’s perspective on the opportunities and challenges within pharmaceutical innovation. He stated, “Data analytics has become a core competency for Pharma. It’s definitely not something you want to outsource. What brought me to Innoplexus is our approach of empowering pharma with customized ecosystems enhanced with relevant data grounded in the life sciences. Our tools and people speak the language of pharma and apply that to our AI and Machine Learning technologies.”
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…